Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Absci Corp files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
4.78
4.78
5.75
5.72
4.53
2.8
Research and development
11.4
44.6
58.9
48.1
63.9
81.4
Selling, general and administrative
5.5
28.8
40.6
37.8
36.2
35.1
Operating expenses
18.1
80
112
121
113
123
Operating income
-13.3
-75.2
-107
-116
-109
-120
Interest expense
0.63
3.43
0.97
1.01
0.57
0.21
Other non-operating income
-1.05
-34.6
1.39
5.05
5.85
5.2
Pre-tax income
-14.4
-110
-105
-110
-103
-115
Income tax
0
-8.9
-0.46
0.1
0.07
0.07
Net income
-14.4
-101
-105
-111
-103
-115
EBITDA
-12.2
-68.6
-93.7
-102
-95.5
-109
EPS, basic
-3.19
-2.08
-1.15
-1.20
-0.94
-0.84
EPS, diluted
-3.19
-2.08
-1.15
-1.20
-0.94
-0.84
Shares, basic (weighted)
15.5
49.7
90.8
92
110
137
Shares, diluted (weighted)
15.5
49.7
90.8
92
110
137
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
69.9
253
60
72.4
41.2
20
Short-term investments
0
71.2
124
Receivables
2.19
0
Other current assets
1.77
8.57
5.86
4.54
5.46
5.28
Total current assets
73.2
273
187
121
134
150
Property, plant and equipment
8.91
52.1
52.7
41.3
29.2
20.9
Lease right-of-use assets
4.48
6.54
5.32
4.49
3.97
2.91
Goodwill
0
21.3
21.3
0
Intangible assets
0
55
51.6
48.3
44.9
41.5
Long-term investments
11.8
Other non-current assets
0.11
1.29
1.28
1.54
0.71
0.38
Total assets
88.6
426
321
217
214
216
Accounts payable
2.12
8.39
2.41
1.5
2.95
2.76
Accrued liabilities
1.57
17.4
20.5
6.55
6.84
6.62
Deferred revenue
2.63
1.35
0.45
3.17
1.12
0.74
Total current liabilities
10.1
33.9
30.3
29.6
28.7
22.8
Long-term debt
4.14
1.12
7.98
4.66
1.26
0
Lease liabilities
3.81
8.97
7.32
5.64
4.43
2.62
Other non-current liabilities
0.75
12.2
0.04
0.3
0.13
1.02
Total liabilities
21.6
60.1
46.6
41.1
34.5
26.8
Total debt
3.52
10.9
7.92
3.99
Paid-in capital
0.64
557
570
583
689
814
Retained earnings
-90.1
-191
-296
-406
-510
-625
Other comprehensive income
0
-0.01
-0.12
-0.04
-0
0.59
Shareholders' equity
-89.4
366
274
176
179
189
Total equity
-89.4
366
274
176
179
189
Total liabilities and equity
88.6
426
321
217
214
216
Shares outstanding
17.9
92.6
92.4
93.1
115
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-14.4
-101
-105
-111
-103
-115
Depreciation and amortization
1.13
6.65
13
14
13.4
11.7
Stock-based compensation
0.42
10.6
12.5
11.4
19.5
18.3
Deferred income tax
0
-8.9
-0.51
-0.05
-0.07
-0.1
Change in receivables
-0.67
2.24
0
Change in payables
0.9
1.57
-0.53
-0.79
1.73
1.09
Cash from operations
-11
-60.6
-81.3
-64.6
-72.4
-92.9
Capital expenditures
-2.18
-38
-16.2
-0.86
-0.4
-1.11
Acquisitions
0
-28.1
-8
0
Purchases of investments
0
-109
-147
-186
-120
Sales and maturities of investments
242
177
69.5
Cash from investing
-2.17
-67.4
-127
81.9
-41.6
-50.2
Debt repaid
-0.5
-1.6
-4.65
-3.01
-3.39
-3.12
Stock issued
0
210
0.66
0.86
82.4
106
Cash from financing
71
336
5.24
-4.48
82.5
106
Net change in cash
57.8
208
-203
12.8
-31.5
-37.1
Free cash flow
-13.2
-98.6
-97.5
-65.5
-72.8
-94
Interest paid
0.51
0.65
0.9
0.97
0.56
0.18
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $9.74 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-8,084.0%
Operating income / revenue.
EBITDA margin
-7,374.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-7,756.0%
Pre-tax income / revenue.
Net margin
-7,756.0%
Net income / revenue.
FCF margin
-6,981.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-6,924.0%
Cash from operations / revenue.
Return on equity (ROE)
-49.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-45.0%
Net income / average total assets.
Return on invested capital (ROIC)
-72.1%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
5,540.0%
Research and development expense / revenue.
SG&A / revenue
2,260.0%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
1,171.0%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
57.0%
Capital expenditures / revenue.
D&A / revenue
710.7%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-38.2%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-21.3%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-10.1%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
5.8%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-11.6%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
1.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-12.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
19.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
24.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
14.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
54.6%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
10.6x
Current assets / current liabilities.
Quick ratio
10.3x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
10.3x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.01
Revenue / diluted weighted shares.
FCF per share
-$0.69
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.69
Cash from operations / diluted weighted shares.
Book value per share
$1.56
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
1,071x
Market cap / revenue.
P/B
6.79x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
8.11x
Market cap / tangible book value, when positive.
EV/Sales
942x
Enterprise value / revenue.
FCF yield
-6.5%
Free cash flow / market cap.
Earnings yield
-7.2%
Net income / market cap (the inverse of P/E).
What was Absci Corp's revenue in fiscal 2025?
Absci Corp reported revenue of $2.8M for fiscal 2025, 38.2% lower than the year before.
Was Absci Corp profitable in fiscal 2025?
No. It reported a net loss of $115.2M.
How much free cash flow did Absci Corp generate in fiscal 2025?
Cash from operations of $92.9M minus capital expenditures of $1.1M left free cash flow of -$94.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.